A large, population-based study from the United Kingdom suggests that there is limited overlap between the risk factors for developing COVID-19 and those for developing severe disease.
The findings appear in the respiratory journal Thorax.
After the researchers adjusted for factors that could influence exposure to SARS-CoV-2, Asian or Asian British ethnicity and high BMI were associated with a higher risk of developing COVID-19.
Allergy Therapeutics plc (LON:AGY) is a market-leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.